A COMPARATIVE EVALUATION OF THE HEALTH ECONOMIC OUTCOMES OF FEBUXOSTAT AND ALLOPURINOL IN GOUT PATIENTS WITH CHRONIC KIDNEY DISEASE

被引：0
|
作者：
Mitri, G. [1 ]
Wittbrodt, E. T. [1 ]
Turpin, R. S. [1 ]
Costa, L. A. [2 ]
Schulman, K. [2 ]
机构：
[1] Takeda Pharmaceut Inc, Med Affairs, Deerfield, IL USA
[2] Outcomes Res Solut Inc, Shrewsbury, MA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2014年 / 73卷
关键词：
D O I：
10.1136/annrheumdis-2014-eular.1625
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0174
引用
收藏
页码：445 / 445
页数：1
相关论文
共 50 条
  • [31] Meta-analysis assessing cardiovascular outcomes with febuxostat versus allopurinol for patients with gout
    Patoulias, D.
    Boulmpou, A.
    Tranidou, A.
    Nikolaidis, A.
    Papadopoulos, C. E.
    Vassilikos, V.
    Bakatselos, S.
    Damianidis, G.
    Doumas, M.
    EUROPEAN HEART JOURNAL, 2021, 42 : 3264 - 3264
  • [32] Protective Effect of Allopurinol Use on Kidney Function Among Patients with Gout and Chronic Kidney Disease
    Vargas-Santos, Ana Beatriz
    Peloquin, Christine
    Zhang, Yuqing
    Neogi, Tuhina
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [33] RENOPROTECTIVE EFFECTS OF FEBUXOSTAT AND ALLOPURINOL IN PATIENTS WITH HYPERURICEMIA AND CHRONIC KIDNEY DISEASE: A META-ANALYSIS
    Edding, Sherida
    Cabral, Brian Michael
    Cating-Cabral, Monica Therese
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2020, 75 (04) : 565 - 565
  • [34] Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease
    Tsuruta, Yuki
    Mochizuki, Toshio
    Moriyama, Takahito
    Itabashi, Mitsuyo
    Takei, Takashi
    Tsuchiya, Ken
    Nitta, Kosaku
    CLINICAL RHEUMATOLOGY, 2014, 33 (11) : 1643 - 1648
  • [35] AS COMPARED WITH ALLOPURINOL ONLY FEBUXOSTAT PRESERVES VASCULAR FUNCTION IN PATIENTS WITH CHRONIC TOPHACEOUS GOUT
    Tausche, A-K.
    Christoph, M.
    Forkmann, M.
    Richter, U.
    Aringer, M.
    Wunderlich, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 704 - 704
  • [36] Comparison of Febuxostat and Allopurinol in the Treatment of Patients with Chronic Kidney Disease Stage 3∼5 with Hyperuricemia
    Liao, Zhimin
    Xu, Lei
    Wan, Bo
    Wang, Liping
    Zhao, Chengzhi
    Wu, Gang
    Xie, Rui
    EMERGENCY MEDICINE INTERNATIONAL, 2022, 2022
  • [37] Febuxostat is superior to allopurinol in delaying the progression of renal impairment in patients with chronic kidney disease and hyperuricemia
    Xin Zhang
    Dapeng Wan
    Guosheng Yang
    Qingping Peng
    Xiaohui Wang
    International Urology and Nephrology, 2019, 51 : 2273 - 2283
  • [38] Febuxostat is superior to allopurinol in delaying the progression of renal impairment in patients with chronic kidney disease and hyperuricemia
    Zhang, Xin
    Wan, Dapeng
    Yang, Guosheng
    Peng, Qingping
    Wang, Xiaohui
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2019, 51 (12) : 2273 - 2283
  • [39] Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease
    Yuki Tsuruta
    Toshio Mochizuki
    Takahito Moriyama
    Mitsuyo Itabashi
    Takashi Takei
    Ken Tsuchiya
    Kosaku Nitta
    Clinical Rheumatology, 2014, 33 : 1643 - 1648
  • [40] Association of Chronic Kidney Disease With Allopurinol Use in Gout Treatment
    Vargas-Santos, Ana Beatriz
    Peloquin, Christine E.
    Zhang, Yuqing
    Neogi, Tuhina
    JAMA INTERNAL MEDICINE, 2018, 178 (11) : 1526 - 1533
12345